Circulating tumour cells
Circulating tumour cells: insights into tumour heterogeneity
7
Gene expression of circulating tumour cells in breast cancer patients
7
Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients
5
Impact of label-free technologies in head and neck cancer circulating tumour cells
12
Circulating tumour cells and EpCAM as tools for diagnostic and mechanistic studies of lung cancer
193
Inertia based microfluidic capture and characterisation of circulating tumour cells for the diagnosis of lung cancer
6
Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancer
35
Heterogeneous expression of EPCAM in human circulating tumour cells from patient-derived xenografts
9
Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression
28
Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients
11
Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device
15
The molecular detection of circulating tumour cells
9
Molecular Analysis of Circulating Tumour Cells in Pancreatic Cancer
172
Biomarkers characterization of circulating tumour cells in breast cancer patients
12
Recent advances in the biology of human circulating tumour cells and metastasis
9
Characterisation of circulating tumour cells in men with advanced prostate cancer and correlation with numbers of circulating and tissue based inflammatory cells
164
Circulating tumour cells in patients with urothelial tumours: Enrichment and in vitro culture
6
Genetic markers in circulating tumour cells as a measure of the metastatic propensity of uveal melanoma
140
Circulating tumour cells in regionally metastatic cutaneous squamous cell carcinoma: A pilot study
5
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
15